<code id='0058477707'></code><style id='0058477707'></style>
    • <acronym id='0058477707'></acronym>
      <center id='0058477707'><center id='0058477707'><tfoot id='0058477707'></tfoot></center><abbr id='0058477707'><dir id='0058477707'><tfoot id='0058477707'></tfoot><noframes id='0058477707'>

    • <optgroup id='0058477707'><strike id='0058477707'><sup id='0058477707'></sup></strike><code id='0058477707'></code></optgroup>
        1. <b id='0058477707'><label id='0058477707'><select id='0058477707'><dt id='0058477707'><span id='0058477707'></span></dt></select></label></b><u id='0058477707'></u>
          <i id='0058477707'><strike id='0058477707'><tt id='0058477707'><pre id='0058477707'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:421
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          The Biogen Aduhelm mess could happen again
          The Biogen Aduhelm mess could happen again

          BiogenrecentlyannounceditwillceaseboththestudyandsaleofitsAlzheimer'sdrugAduhelm.JessicaRinaldi/TheB

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

          1:30Aboywalksthroughafloodedareainal-SagainorthofOmdurmanonAugust6,2023.Torrentialrainshavedestroyed